Published in Cancer Weekly, February 14th, 2006
"Human epidermal growth factor receptor 2 (HER2) is overexpressed in 25%-30% of ovarian carcinoma cases and a correlation between increased HER2 expression and decreased survival has been demonstrated. HER2 is a ligand-less 3 member of the HER family that functions as the preferred coreceptor for epidermal 3 growth factor receptor (EGFR), HER3, and HER4," researchers in the United States reported.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.